Review summarizes antibody drug conjugates' clinical activity in urothelial carcinoma, highlighting implications for treatment.
Key Points
This review aims to summarize the current landscape of antibody drug conjugates in urothelial carcinoma, focusing on clinical implications and emerging strategies.
Review of current evidence and efficacy of antibody drug conjugates in urothelial carcinoma.
Analysis of emerging agents and combination strategies in various disease settings.
Discussion of clinically relevant toxicities and mechanisms of resistance.
ADCs like enfortumab vedotin targeting Nectin-4 have replaced platinum-based chemotherapy as the standard of care.
Next-generation ADCs are being evaluated for improved efficacy and reduced toxicity.
Focus on biomarker-driven patient selection aims to optimize treatment outcomes while limiting adverse effects.